Fesen M R, Pommier Y, Leteurtre F, Hiroguchi S, Yung J, Kohn K W
Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
Biochem Pharmacol. 1994 Aug 3;48(3):595-608. doi: 10.1016/0006-2952(94)90291-7.
The inhibition of HIV-1 integrase by flavones and related compounds was investigated biochemically and by means of structure-activity relationships. Purified enzyme and synthetic oligonucleotides were used to assay for three reactions catalysed by integrase: (1) processing of 3' termini by cleavage of the terminal dinucleotide; (2) strand transfer, which models the integration step; and (3) "disintegration," which models the reversal of the strand transfer reaction. Inhibitions of all three reactions by flavones generally occurred in parallel, but caffeic acid phenethyl ester (CAPE) appeared to inhibit reaction 2 selectively. CAPE, however, inhibited reactions 1 and 3 effectively when preincubated with the enzyme, suggesting that this compound differs from the flavones primarily in requiring more time to block the enzyme. The core integrase fragment consisting of amino acids 50-212 retained the ability to catalyse reaction 3, and flavones and CAPE retained the ability to inhibit. Hence, the putative zinc-finger region that is deleted in this fragment is probably not the target of inhibition. Inhibition by flavones usually required the presence of at least one ortho pair of phenolic hydroxyl groups and at least one or two additional hydroxyl groups. Potency was enhanced by the presence of additional hydroxyl groups, especially when present in ortho pairs or in adjacent groups of three. Inhibitory activity was reduced or eliminated by methoxy or glycosidic substitutions or by saturation of the 2,3 double bond. These structure-activity findings for flavones were generally concordant with those previously reported for reverse transcriptase and topoisomerase II. These findings are discussed in the context of a review of the effects of flavones on various enzymes, the possible mechanisms of inhibition, and the potential for building upon a general pharmacophore to generate target specificity.
通过生物化学方法并借助构效关系研究了黄酮类化合物及相关化合物对HIV-1整合酶的抑制作用。使用纯化的酶和合成寡核苷酸来检测整合酶催化的三种反应:(1)通过切割末端二核苷酸对3'末端进行加工;(2)链转移,模拟整合步骤;(3)“解整合”,模拟链转移反应的逆转。黄酮类化合物对所有三种反应的抑制通常是平行发生的,但咖啡酸苯乙酯(CAPE)似乎选择性地抑制反应2。然而,当与酶预孵育时,CAPE有效地抑制了反应1和3,这表明该化合物与黄酮类化合物的主要区别在于需要更多时间来阻断酶。由氨基酸50 - 212组成的核心整合酶片段保留了催化反应3的能力,黄酮类化合物和CAPE也保留了抑制能力。因此,在该片段中缺失的假定锌指区域可能不是抑制的靶点。黄酮类化合物的抑制通常需要至少一对邻位酚羟基和至少一个或两个额外的羟基。额外羟基的存在增强了效力,特别是当它们以邻位对或相邻的三个基团存在时。甲氧基或糖苷取代或2,3双键饱和会降低或消除抑制活性。黄酮类化合物的这些构效关系发现通常与先前报道的逆转录酶和拓扑异构酶II的结果一致。在综述黄酮类化合物对各种酶的作用、可能的抑制机制以及基于通用药效团产生靶点特异性的潜力的背景下讨论了这些发现。